LSTA Lisata Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LSTA

Price (delayed)

$1.435

Market cap

$12.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.64

Enterprise value

$2.49M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 30

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease. The Company’s current product candidates include: XOWNA® (CLBS16), the ...

Highlights
The EPS has grown by 26% YoY and by 12% from the previous quarter
The net income has grown by 23% YoY and by 11% from the previous quarter
The revenue has dropped by 91% year-on-year and by 41% since the previous quarter
The gross profit has plunged by 91% YoY and by 41% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.caladrius.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of LSTA

LSTA stock price

How has the Lisata Therapeutics stock price performed over time
Intraday
-3.04%
1 week
-2.38%
1 month
-7.42%
1 year
-37.34%
YTD
-22.85%
QTD
-57.79%

Financial performance

How have Lisata Therapeutics's revenue and profit performed over time
Revenue
$100,000
Gross profit
$100,000
Operating income
-$16.43M
Net income
-$14.62M
Gross margin
100%
Net margin
-14,621%
The revenue has dropped by 91% year-on-year and by 41% since the previous quarter
The gross profit has plunged by 91% YoY and by 41% from the previous quarter
The operating margin has plunged by 61% from the previous quarter
The net margin has plunged by 52% from the previous quarter

Price vs fundamentals

How does LSTA's price correlate with its fundamentals

Growth

What is Lisata Therapeutics's growth rate over time

Valuation

What is Lisata Therapeutics stock price valuation
P/E
N/A
P/B
1.59
P/S
130.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.88
The EPS has grown by 26% YoY and by 12% from the previous quarter
LSTA's price to book (P/B) is 63% higher than its 5-year quarterly average of 1.0 but 37% lower than its last 4 quarters average of 2.6
LSTA's equity has plunged by 61% YoY and by 25% from the previous quarter
The revenue has dropped by 91% year-on-year and by 41% since the previous quarter
The stock's price to sales (P/S) is 22% less than its last 4 quarters average of 172.9

Efficiency

How efficient is Lisata Therapeutics business performance
LSTA's ROE has plunged by 65% YoY and by 12% from the previous quarter
The ROS has plunged by 52% from the previous quarter
Lisata Therapeutics's return on assets has shrunk by 52% YoY and by 9% QoQ

Dividends

What is LSTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LSTA.

Financial health

How did Lisata Therapeutics financials performed over time
The company's total assets has shrunk by 56% YoY and by 22% QoQ
LSTA's current ratio is down by 36% YoY and by 13% QoQ
The debt is 100% less than the equity
LSTA's equity has plunged by 61% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.